Boosted Atazanavir
PreclinicalSmall molecule
Boosted Atazanavir is one of 18 small molecule programs targeting Osteopenia. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Osteopenia
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Evista
Eli LillyApproved
Deltavit
HHyundai Pharmaceutical Co., LTD.
Approved
Jadelle
IItalian Network for Tumor Biotherapy Foundation
Approved
Forteo
AAlmaject
Approved
Zometa
PfizerPhase 3
Prolia
AmgenPhase 3
Boniva
CConrado Roberto Hoffmann Filho
Phase 3
Ozempic
Novo NordiskPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteopenia1 trial
Children1 trial
Atazavanir/Ritonavir-based HAART in Children
Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·Phase 2·NCT01656109·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Boosted Atazanavir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPhoenix Children's Hospital